CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 380 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $928,324 | +9.5% | 17,188 | +38.1% | 0.00% | 0.0% |
| Q1 2024 | $848,047 | +405.2% | 12,442 | +236.5% | 0.00% | – |
| Q3 2023 | $167,852 | -33.6% | 3,698 | -17.9% | 0.00% | -100.0% |
| Q2 2023 | $252,967 | -60.1% | 4,506 | -71.1% | 0.00% | -66.7% |
| Q4 2022 | $633,896 | -87.6% | 15,594 | -80.9% | 0.00% | -93.0% |
| Q1 2022 | $5,122,000 | +139.9% | 81,592 | +189.6% | 0.04% | +168.8% |
| Q4 2021 | $2,135,000 | +16.4% | 28,178 | +148.8% | 0.02% | -23.8% |
| Q2 2021 | $1,834,000 | -16.5% | 11,327 | -21.0% | 0.02% | -32.3% |
| Q4 2020 | $2,196,000 | +50.4% | 14,344 | -17.8% | 0.03% | +47.6% |
| Q3 2020 | $1,460,000 | +79.6% | 17,455 | +30.8% | 0.02% | -19.2% |
| Q4 2019 | $813,000 | – | 13,348 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |